NUVECTIS PHARMA INC (NVCT) Fundamental Analysis & Valuation

NASDAQ:NVCT • US67080T1088

Current stock price

8.9 USD
+0.11 (+1.25%)
At close:
8.9 USD
0 (0%)
After Hours:

This NVCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NVCT Profitability Analysis

1.1 Basic Checks

  • NVCT had negative earnings in the past year.
  • NVCT had a negative operating cash flow in the past year.
  • In the past 5 years NVCT always reported negative net income.
  • NVCT had a negative operating cash flow in each of the past 5 years.
NVCT Yearly Net Income VS EBIT VS OCF VS FCFNVCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • NVCT has a Return On Assets of -91.05%. This is in the lower half of the industry: NVCT underperforms 73.26% of its industry peers.
  • With a Return On Equity value of -156.80%, NVCT is not doing good in the industry: 65.12% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -91.05%
ROE -156.8%
ROIC N/A
ROA(3y)-103.06%
ROA(5y)-119.25%
ROE(3y)-178.28%
ROE(5y)-194.62%
ROIC(3y)N/A
ROIC(5y)N/A
NVCT Yearly ROA, ROE, ROICNVCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NVCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVCT Yearly Profit, Operating, Gross MarginsNVCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NVCT Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NVCT has more shares outstanding
  • Compared to 5 years ago, NVCT has more shares outstanding
  • NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVCT Yearly Shares OutstandingNVCT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
NVCT Yearly Total Debt VS Total AssetsNVCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • NVCT has an Altman-Z score of 3.93. This indicates that NVCT is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.93, NVCT is doing good in the industry, outperforming 70.93% of the companies in the same industry.
  • NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.93
ROIC/WACCN/A
WACCN/A
NVCT Yearly LT Debt VS Equity VS FCFNVCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 10M -10M

2.3 Liquidity

  • NVCT has a Current Ratio of 2.38. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
  • NVCT has a Current ratio of 2.38. This is in the lower half of the industry: NVCT underperforms 73.26% of its industry peers.
  • NVCT has a Quick Ratio of 2.38. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NVCT (2.38) is worse than 69.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
NVCT Yearly Current Assets VS Current LiabilitesNVCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. NVCT Growth Analysis

3.1 Past

  • The earnings per share for NVCT have decreased by -9.01% in the last year.
EPS 1Y (TTM)-9.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NVCT will show a small growth in Earnings Per Share. The EPS will grow by 3.49% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.16%
EPS Next 2Y-4.78%
EPS Next 3Y3.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVCT Yearly Revenue VS EstimatesNVCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 5M 10M 15M 20M 25M
NVCT Yearly EPS VS EstimatesNVCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. NVCT Valuation Analysis

4.1 Price/Earnings Ratio

  • NVCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NVCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCT Price Earnings VS Forward Price EarningsNVCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCT Per share dataNVCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.78%
EPS Next 3Y3.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVCT Dividend Analysis

5.1 Amount

  • No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NVCT Fundamentals: All Metrics, Ratios and Statistics

NUVECTIS PHARMA INC

NASDAQ:NVCT (4/24/2026, 8:00:02 PM)

After market: 8.9 0 (0%)

8.9

+0.11 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-12
Inst Owners17.19%
Inst Owner Change-0.25%
Ins Owners41.59%
Ins Owner Change6.72%
Market Cap235.76M
Revenue(TTM)N/A
Net Income(TTM)-28.87M
Analysts83.33
Price Target18.87 (112.02%)
Short Float %10.19%
Short Ratio26.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.44%
Min EPS beat(2)-30.72%
Max EPS beat(2)-2.16%
EPS beat(4)0
Avg EPS beat(4)-13.11%
Min EPS beat(4)-30.72%
Max EPS beat(4)-2.16%
EPS beat(8)3
Avg EPS beat(8)-5.63%
EPS beat(12)4
Avg EPS beat(12)-4.07%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.91%
PT rev (3m)1.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-20.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.8
P/tB 12.8
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -91.05%
ROE -156.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.06%
ROA(5y)-119.25%
ROE(3y)-178.28%
ROE(5y)-194.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z 3.93
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.89%
EPS Next Y-5.16%
EPS Next 2Y-4.78%
EPS Next 3Y3.49%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.22%
EBIT Next 3Y-26.97%
EBIT Next 5YN/A
FCF growth 1Y-30.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.72%
OCF growth 3YN/A
OCF growth 5YN/A

NUVECTIS PHARMA INC / NVCT Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NUVECTIS PHARMA INC (NVCT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVCT.


Can you provide the valuation status for NUVECTIS PHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to NUVECTIS PHARMA INC (NVCT). This can be considered as Overvalued.


What is the profitability of NVCT stock?

NUVECTIS PHARMA INC (NVCT) has a profitability rating of 0 / 10.


What is the expected EPS growth for NUVECTIS PHARMA INC (NVCT) stock?

The Earnings per Share (EPS) of NUVECTIS PHARMA INC (NVCT) is expected to decline by -5.16% in the next year.